United States: Food, Drugs, Healthcare, Life Sciences

On June 22, 2026, the U.S. District Court for the District of Columbia granted summary judgment to a group of Supplemental Nutrition Assistance Program (SNAP) participants challenging U.S. Department of Agriculture (USDA) approvals of state SNAP pilot projects in Colorado, Iowa, Nebraska, Tennessee, and West Virginia.1

The Centers for Medicare & Medicaid Services (CMS) recently released its proposed Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center...

The Federal Circuit examined whether a provisional patent application's disclosure of a C2-C12-alkyl group could support a later patent claiming a C1-C12-alkyl structure, when an intervening public disclosure by a competitor revealed the C1-alkyl compound. The court's decision hinged on whether alleged typographical errors in the provisional application could establish written description support for the broader claim scope.

The Federal Circuit affirmed a district court's invalidity ruling on Enanta Pharmaceuticals' COVID-19 treatment patent, centering on whether a provisional application's reference to "C2-C12 alkyls" provided adequate written description support for later claims covering C1 alkyls. The appeal raised critical questions about typographical errors in patent specifications and the boundaries of written description requirements when expanding chemical compound definitions between provisional and utility patent app

The FDA has granted interchangeability designation to TRUXIMA® (rituximab-abbs), making it the first rituximab biosimilar to achieve this status in the United States. This milestone allows pharmacists to substitute TRUXIMA® for the reference product RITUXAN® without prescriber intervention, potentially expanding access to this treatment for conditions including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.

Strategic seed capital works best when investors help founders see what their technology can become - not just what it does today. Dr. Gopal Chopra, founding partner of Validare Capital, shares how his background as a neurosurgeon, entrepreneur and investor informs the firm's approach to early-stage investing, targeting companies that can be built quickly and efficiently with lean teams while addressing critical market needs across life sciences and data analytics.

The Centers for Medicare & Medicaid Services has proposed sweeping changes to hospital outpatient and ambulatory surgical center payment systems for 2027, including a dramatic reduction in 340B drug payments from ASP +6% to ASP -33.4% and new mandatory attestation requirements for provider-based status. These proposals would fundamentally reshape hospital revenue streams through payment cuts, site-neutral policies, and enhanced compliance oversight.

On June 22, 2026, the U.S. District Court for the District of Columbia granted summary judgment to a group of Supplemental Nutrition Assistance Program (SNAP) participants challenging U.S. Department of Agriculture (USDA) approvals of state SNAP pilot projects in Colorado, Iowa, Nebraska, Tennessee, and West Virginia.1

The Centers for Medicare & Medicaid Services (CMS) recently released its proposed Calendar Year (CY) 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center...